A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Relapsed and/or Refractory Multiple Myeloma (RRMM)
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +4.8
5 insiders sold shares within a month
Since Nov 4, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 3
- Patients
- 915 (planned)
- Started
- Jan 2, 2026
- Main results expected
- May 21, 2029
- Fully finished
- Aug 23, 2034
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Occurrence of Treatment Emergent Adverse Events (TEAEs)
Measured over: Up to 5 years
Severity of TEAEs
Measured over: Up to 5 years
Occurrence of Adverse Events of Special Interest (AESI)
Measured over: Up to 5 years
Severity of AESIs
Measured over: Up to 5 years
Occurrence of Serious Adverse Events (SAEs)
Measured over: Up to 5 years
Severity of SAEs
Measured over: Up to 5 years
Minimal Residual Disease (MRD)-negative Complete Response (CR)
Measured over: At 12 months
Progression-Free Survival (PFS) per IMWG response criteria as determined by BIRC
Measured over: Up to 5 years
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 4.8, since 2026-11-04, fades (half-life)
Raw record changes
- none yet
Trial ID NCT07222761 · record last updated 2026-11-04 · checked 2026-11-09 15:47 UTC